Targeted combination has synergy in MCL
- PMID: 29662152
- DOI: 10.1038/s41571-018-0021-3
Targeted combination has synergy in MCL
Comment on
-
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. N Engl J Med. 2018. PMID: 29590547 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
